NMN and NR Safety in Adolescents (Ages 12 to 17): What the Evidence Shows

Why NAD Precursors Attract Adolescent Interest

The consumer longevity market reached an estimated $27 billion in 2024, and social-media promotion increasingly targets younger demographics. NMN and NR are marketed as "anti-aging" compounds that raise intracellular nicotinamide adenine dinucleotide (NAD+), a coenzyme required for mitochondrial electron transport, DNA repair via PARP enzymes, and sirtuin-mediated gene silencing 1. Adolescents seeking cognitive enhancement, athletic performance gains, or metabolic optimization encounter these products on platforms with minimal age-gating.

The biological rationale in adults rests on the observation that tissue NAD+ declines with age. A 2016 study by Massudi et al. measured a 50% reduction in dermal NAD+ between ages 20 and 60 2. Adolescents, however, maintain peak NAD+ biosynthesis through the de novo pathway from tryptophan and the salvage pathway recycling nicotinamide. Supplementing a system already operating near physiological maximum introduces a different risk-benefit calculus than replenishing a depleted adult pool.

The Adult Safety Record

Short-term tolerability in adults is the only human evidence base. A 2022 randomized, double-blind trial by Yi et al. (N=80, ages 40 to 65) administered 1,000 mg/day NMN orally for 60 days and reported no serious adverse events, with transient flushing and mild GI discomfort in 8% of participants 3. For NR, the CHROMAVIT trial by Martens et al. (2018, N=24) used 1,000 mg/day for six weeks in healthy older adults, finding no clinically significant safety signals and a confirmed rise in whole-blood NAD+ of 60% 4.

Yoshino et al. (Science, 2021) demonstrated that 250 mg/day NMN for 10 weeks improved skeletal-muscle insulin signaling in postmenopausal prediabetic women (N=25), with no adverse events exceeding mild GI complaints 5. This is the highest-impact NMN efficacy trial to date, but enrolled only women aged 55 to 75.

None of these trials included participants under 18. The longest published NMN study in humans ran 12 weeks. Chronic exposure data spanning years (the typical supplementation pattern promoted online) do not exist even in adults.

Pharmacological Concerns Specific to Puberty

Adolescence between ages 12 and 17 involves rapid changes in body composition, hormonal milieu, and organ maturation. Three pharmacological intersections with NAD metabolism merit specific caution.

Growth-plate biology. Longitudinal bone growth depends on chondrocyte proliferation regulated partly by the mTOR pathway. NAD+ activates SIRT1, which modulates mTOR signaling 6. Whether exogenous NAD elevation could accelerate or disrupt epiphyseal plate closure is entirely unstudied. Animal models show that SIRT1 overexpression alters endochondral ossification timing in mice, but translation to human adolescents remains speculative.

Pubertal endocrine axes. The hypothalamic-pituitary-gonadal (HPG) axis activates during puberty with precise timing. NAD-dependent enzymes participate in steroidogenesis. In vitro, elevated NAD+ increases testosterone synthesis in Leydig cells 7. The clinical significance of oral NMN supplementation on pubertal testosterone or estradiol trajectories is unknown, but the theoretical concern justifies caution.

Neurodevelopment. The prefrontal cortex undergoes synaptic pruning and myelination through the mid-20s. NAD+ is consumed by CD38 and PARP1 during neural remodeling. Artificially elevating NAD+ during active pruning could theoretically preserve synapses that would otherwise be eliminated, a process analogous to reduced pruning seen in some neurodevelopmental conditions 8. No human data address this hypothesis.

Regulatory and Legal Status

The FDA classifies NR (as Niagen) with New Dietary Ingredient (NDI) notification status granted to ChromaDex in 2016. NMN occupied a regulatory gray zone until the FDA's 2022 determination that NMN could not be marketed as a dietary supplement because it was being investigated as a new drug (by Metro International Biotech). This ruling was challenged, and as of early 2026, NMN products remain available from multiple retailers without consistent enforcement 9.

Neither compound carries pediatric labeling. The Dietary Supplement Health and Education Act (DSHEA) of 1994 does not require manufacturers to demonstrate safety in minors before sale. Parents purchasing these products for adolescents bear full liability for outcomes.

The American Academy of Pediatrics (AAP) has issued general guidance discouraging dietary supplement use in children and adolescents absent documented deficiency, citing the 2016 clinical report on performance-enhancing substances 10.

What About Niacin and Niacinamide?

Nicotinic acid (niacin, vitamin B3) and nicotinamide have established pediatric safety profiles at RDA doses (12 to 16 mg/day for ages 9 to 13; 16 mg/day for ages 14 to 18) because they are essential nutrients with decades of observational data 11. These compounds also serve as NAD precursors through the Preiss-Handler and salvage pathways.

The distinction matters. NMN and NR bypass rate-limiting steps in NAD synthesis, producing supraphysiological NAD+ elevations that B3 vitamins at RDA doses do not achieve. A 2020 pharmacokinetic study showed that 1,000 mg NR raised blood NAD+ 2.7-fold within two weeks in adults 12. This magnitude of NAD+ elevation in a developing system has never been characterized.

Physicians occasionally prescribe high-dose niacin (500 to 2,000 mg) for adolescent familial hyperlipidemia under close monitoring, but this practice targets a specific lipid endpoint with known hepatic risk and is unrelated to "NAD optimization" goals.

Animal Data Relevant to Developing Organisms

Murine studies offer limited but notable signals. Mills et al. (2016) administered NMN to mice starting at 5 months of age (approximate adult equivalent) and observed improved insulin sensitivity and lipid profiles over 12 months 13. No published study has administered NMN or NR to juvenile mice during a developmental window analogous to human puberty.

A 2021 study by Kiss et al. in aged mice showed NMN improved neurovascular coupling and cognitive function 14. The investigators specifically noted that effects in young mice were minimal, consistent with the hypothesis that NAD supplementation provides benefit primarily when endogenous NAD is depleted. Young organisms may not derive the same benefit and could be exposed to off-target effects that older organisms, with lower baseline NAD+, would not experience.

Risk Stratification: When Might an Adolescent Encounter NAD Precursors

Three scenarios place adolescents in proximity to these compounds.

Scenario 1: Self-directed supplementation. Teens purchasing NMN online without parental or medical oversight. This carries the highest risk due to unverified product quality, unknown dose-response in developing bodies, and absence of monitoring.

Scenario 2: Parent-directed supplementation. A parent interested in longevity medicine extending their regimen to their child. While product quality may be higher, the fundamental absence of pediatric data remains unchanged.

Scenario 3: Research enrollment. A supervised clinical trial with IRB approval, pediatric dosing protocols, growth monitoring, and stopping rules. This is the only context in which adolescent exposure to NMN/NR could generate useful safety data. No such trial is registered on ClinicalTrials.gov as of May 2026.

What Clinicians Should Communicate to Families

Dr. Charles Brenner, the discoverer of the NR kinase pathway, has stated publicly: "There is no reason to give NAD precursors to young, healthy people whose NAD metabolism is intact" 15. This position aligns with the broader principle that supplementation should address a documented deficit or a condition with evidence of benefit.

For adolescents presenting with fatigue, cognitive complaints, or athletic performance concerns, clinicians should evaluate for iron deficiency, thyroid dysfunction, sleep debt, and mood disorders before considering any supplement. Behavioral interventions (consistent sleep of 8 to 10 hours per the CDC adolescent sleep guidelines, regular physical activity, adequate protein intake) support endogenous NAD+ cycling through normal metabolic flux without exogenous intervention 16.

Monitoring Framework If Exposure Has Already Occurred

For clinicians encountering an adolescent already taking NMN or NR, a pragmatic monitoring approach includes:

Baseline and quarterly labs: comprehensive metabolic panel, fasting insulin, IGF-1, hepatic transaminases, complete blood count, and uric acid (NAD metabolism generates uric acid as a downstream metabolite). Growth velocity should be tracked on standard CDC growth charts with attention to any deviation from established percentile.

Tanner staging at each visit documents pubertal progression. Any acceleration or deceleration relative to expected tempo warrants discontinuation and endocrine referral.

Liver function monitoring is particularly relevant given that NMN is metabolized hepatically and high-dose niacin (a related NAD precursor) carries known hepatotoxicity risk at pharmacological doses 17.

Discontinuation should be advised in all cases, with explanation that absence of harm in adult short-term trials does not constitute evidence of safety in a developing organism over months or years.

The Distinction Between "No Evidence of Harm" and "Evidence of Safety"

Marketing materials for NAD precursors frequently cite the adult tolerability data as proof of safety. This conflation is a logical error that carries particular weight in pediatric contexts. Thalidomide was well-tolerated in adults. Fluoroquinolones are safe in adults but damage developing cartilage. The absence of a signal in 60-day adult trials provides zero information about 5-year exposure beginning at age 14.

The Endocrine Society's 2017 guidelines on pediatric drug evaluation emphasize that "children are not small adults" and that developmental pharmacology requires dedicated study 18. Until NMN or NR completes a Phase I/II pediatric safety trial with growth, pubertal, neurocognitive, and metabolic endpoints, the evidence base for adolescent use is a blank page.

Practical Alternatives for Adolescent NAD+ Support

Adolescents concerned about cellular energy and mitochondrial function can support NAD+ metabolism through validated, low-risk strategies:

Dietary niacin equivalents from protein-rich foods (chicken breast provides approximately 14 mg niacin per 100 g) meet or exceed the RDA without supplementation. Tryptophan from dairy, eggs, and turkey feeds the de novo NAD synthesis pathway. Regular aerobic exercise increases NAMPT expression, the rate-limiting enzyme in the NAD salvage pathway, by 30 to 50% in skeletal muscle 19.

Sleep restriction to fewer than 7 hours reduces hepatic NAD+ in animal models. The single most impactful intervention for an adolescent seeking to "optimize NAD" is sleeping 8 to 10 hours nightly, a recommendation supported by the American Academy of Sleep Medicine position statement 20.

These behavioral interventions carry no risk, cost nothing, and address the physiological pathways that NMN/NR target pharmacologically. For a 14-year-old with intact NAD metabolism, sleep and exercise achieve what a capsule cannot.